Plain-English translation of NCT06156683 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Researchers are studying the safety of Kesimpta, a multiple sclerosis medication, when used during pregnancy. This study will compare pregnancy outcomes—including birth defects, miscarriage, and newborn health—in women with MS who were exposed to Kesimpta during pregnancy versus women who took other MS medications or no medications. The information comes from medical records in Denmark, Sweden, and the United States.
Women with multiple sclerosis often need to keep taking their medications during pregnancy to stay healthy, but there is limited real-world information about whether this medication is safe for both mother and baby. This study aims to fill that gap by looking at actual pregnancy outcomes in large numbers of women.
You likely qualify if…
You likely don't qualify if…
You would not need to visit a clinic or take any new medications. Instead, researchers will review your existing medical records from healthcare providers in your country to gather information about your pregnancy, the medications you took, and your baby's health outcomes. This is a retrospective study, meaning it looks back at records that have already been collected.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Switzerland
Sponsor
Novartis Pharmaceuticals
Enrollment target
~1,500 participants
Started
June 2024
Primary completion
February 2028
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.